Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 13;86(2):255-60.
Print 2013 Jun.

Clinical characteristics of refractory myasthenia gravis patients

Joome Suh  1 , Jonathan M Goldstein, Richard J Nowak
Affiliations

Clinical characteristics of refractory myasthenia gravis patients

Joome Suh et al. Yale J Biol Med. .

Abstract

Background: A subset of myasthenia gravis (MG) patients is refractory to standard therapies. Identifying the characteristics of this population is essential as newer treatment strategies emerge that may be more effective in this group.

Objective: The aim of our study is to describe the clinical features of refractory MG patients and compare them to those of non-refractory patients.

Methods: A retrospective chart review was completed of 128 MG patients referred to a tertiary neuromuscular clinic from 2003 to 2011. Patients were classified as refractory or non-refractory based on predefined criteria, and clinical features were compared.

Results: Nineteen out of 128 patients were classified as refractory (14.8 percent). Compared to the non-refractory patients, the refractory patients were more likely to be younger at onset, female, thymomatous, and MuSK-antibody positive.

Conclusion: Refractory MG patients represent a small but distinct group for whom exploring newer therapeutic approaches and immunopathologic differences is warranted.

Keywords: clinical features; myasthenia gravis; refractory disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of age of onset in refractory vs. non-refractory MG patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Drachman DB. Myasthenia gravis. N Eng J Med. 1994;330(25):1797–1810. - PubMed
    1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–490. - PMC - PubMed
    1. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843–2854. - PMC - PubMed
    1. Silvestri NJ, Wolfe GI. Myasthenia gravis. Semin Neurol. 2012;32(3):215–226. - PubMed
    1. Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve. 2010;41(3):375–378. - PubMed